Iovance Biotherapeutics, Inc. (IOVA) stock
IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Iovance Biotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Iovance Biotherapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$276.26M. For fiscal 2025 it was -$390.49M. The highest annual figure on record is -$14.44K in fiscal 2009.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$390.49M | – |
| FY2024 | Dec 31, 2024 | -$384.02M | – |
| FY2023 | Dec 31, 2023 | -$448.99M | – |
| FY2022 | Dec 31, 2022 | -$389.57M | – |
| FY2021 | Dec 31, 2021 | -$339.59M | – |
| FY2020 | Dec 31, 2020 | -$260.80M | – |
| FY2019 | Dec 31, 2019 | -$205.70M | – |
| FY2018 | Dec 31, 2018 | -$127.30M | – |
| FY2017 | Dec 31, 2017 | -$91.93M | – |
| FY2016 | Dec 31, 2016 | -$52.66M | – |
| FY2015 | Dec 31, 2015 | -$26.86M | – |
| FY2014 | Dec 31, 2014 | -$11.95M | – |
| FY2013 | Dec 31, 2013 | -$22.63M | – |
| FY2012 | Dec 31, 2012 | -$8.13M | – |
| FY2011 | Dec 31, 2011 | -$21.22M | – |
| FY2010 | Dec 31, 2010 | -$756.82K | – |
| FY2009 | Dec 31, 2009 | -$14.44K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$78.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$69.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$85.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$104.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$118.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$83.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$79.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$98.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$114.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$118.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$115.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$107.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$108.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$104.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$97.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$97.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$89.92M | – |
| Q4 FY2021 | Dec 31, 2021 | -$98.12M | – |
| Q3 FY2021 | Sep 30, 2021 | -$85.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$81.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$75.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$68.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$58.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$63.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$70.56M | – |
| Q4 FY2019 | Dec 31, 2019 | -$64.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$51.30M | – |
| Q2 FY2019 | Jun 30, 2019 | -$49.88M | – |
| Q1 FY2019 | Mar 31, 2019 | -$39.72M | – |
| Q4 FY2018 | Dec 31, 2018 | -$34.69M | – |
| Q3 FY2018 | Sep 30, 2018 | -$34.81M | – |
| Q2 FY2018 | Jun 30, 2018 | -$31.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$26.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$25.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$22.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$23.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.66M | – |
| Q4 FY2016 | Dec 31, 2016 | -$15.63M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.83M | – |
See a number that looks wrong?